Clinical practice guidelines for the use of intravenous polymyxins in children: a protocol

Published on Nov. 30, 2023Total Views: 1124 times Total Downloads: 482 times Download Mobile

Author: Lin TANG ^1, ² Shan SHEN ^1, ² Dong-Na ZOU ¹ Bing LENG ^1, ² Rui-Fang NIE ¹ Yan JIN ³ Li-Kai LIN ⁴ Xian-Tao ZENG ⁵ Suo-Di ZHAI ^6, ⁷ Ling-Li ZHANG ⁸ Ning HOU ^1, ²

Affiliation: 1. Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China 2. Evidence-Based Pharmacy Specialized Committee of Shandong Pharmaceutical Association, Jinan 250021, China 3. Laboratory of Medical Examination, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China 4. Hospital Management Institute Wuhan University, Wuhan 430071, China 5. Center of Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 6. Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China 7. Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China 8. Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu 610041, China

Keywords: Polymyxins Pediatric medication Anti-infection Guideline protocol

DOI: 10.19960/j.issn.1005-0698.202311005

Reference: Lin TANG, Shan SHEN, Dong-Na ZOU, Bing LENG, Rui-Fang NIE, Yan JIN, Li-Kai LIN, Xian-Tao ZENG, Suo-Di ZHAI, Ling-Li ZHANG, Ning HOU.Clinical practice guidelines for the use of intravenous polymyxins in children: a protocol[J].Yaowu Liuxingbingxue Zazhi,2023, 32(11):1231-1237.DOI: 10.19960/j.issn.1005-0698.202311005.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

In order to promote the rational use of polymyxins in children, Shandong Pharmaceutical Association set up a project, led by Shandong Provincial Hospital Affiliated to Shandong First Medical University, and organized well-known experts in relevant fields in the whole country to compile the "Clinical practice guidelines for the use of intravenous polymyxins in children" with reference to the WHO Handbook for Guideline Development and the Reporting Items for Practice Guidelines in Healthcare (RIGHT) standards and requirements. This protocol of the guideline will mainly introduce the background, purpose and significance of the guideline development, the application group, the method and process of making the guide, so as to make the whole process of writing the guideline standardized and transparent, and improve the rigor and science of the guide through comprehensive evidence retrieval, standardized evidence evaluation, and scientific recommendation formation methods.

Full-text

Please download the PDF version to read the full text: download

References

1.Ross S, Burke FG. The use of aerosporin (polymyxin B) in specific and nonspecific enteritis in infants and children[J]. Med Ann Dist Columbia, 1949, 18(9): 441-448. https://pubmed.ncbi.nlm.nih.gov/18138615/.

2.Guassardo G. La colimicina in pediatria [Colimycin in pediatrics][J]. Minerva Med, 1958, 49(97): 4494-4497.https://pubmed.ncbi.nlm.nih.gov/13622333/.

3.Moxon CA, Paulus S. Beta-lactamases in Entero-bacteriaceae infections in children[J]. J Infect, 2016, 72(Suppl): S41-S49. DOI: 10.1016/j.jinf.2016.04.021.

4.Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis[J]. Cochrane Database Syst Rev, 2017, 4(4): CD004197. DOI: 10.1002/14651858.CD004197.pub5.

5.Thomas R, Velaphi S, Ellis S, et al. The use of polymyxins to treat carbapenem resistant infections in neonates and children[J]. Expert Opin Pharmacother, 2019, 20(4): 415-422. DOI: 10.1080/14656566.2018.1559817.

6.Chiotos K, Hayes M, Gerber JS, et al. Treatment of carbapenem-resistant Enterobacteriaceae infections in children[J]. J Pediatric Infect Dis Soc, 2020, 9(1): 56-66. DOI: 10.1093/jpids/piz085.

7.Tang L, Zhao K, Hou N. Off-label use of antimicrobials among hospitalized children: a retrospective study of 3,406 patients[J]. Front Microbiol, 2023, 14: 1173042. DOI: 10.3389/fmicb.2023.1173042.

8.杨克虎, 主译. 世界卫生组织指南制订手册[M].兰州: 兰州大学出版社, 2013.

9.Brouwers MC, Kerkvliet K, Spithoff K, et al. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines[J]. BMJ, 2016, 354: i4852. DOI: 10.1136/bmj.i1152.

10.Chen Y, Yang K, Marusic A, et al. A reporting tool for practice guidelines in health care: The RIGHT Statement[J]. Ann Intern Med, 2017, 166(2): 128-132.DOI: 10.7507/1672-2531.202106002.

11.谭力铭, 范曼如, 申泉，等. 临床实践指南制订方法——指南的规范化报告[J].中国循证心血管医学杂志, 2019, 11(8): 900-904. [Tan LM, Fan MR, Shen Q, et al. Methodology for clinical practice guidelines-standardized report of guidelines[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2019, 11(8): 900-904.] DOI: 10.3969/j.issn.1674-4055.2019.08.02.

12.Global antimicrobial resistance and use surveillance system (GLASS) report 2022[R]. Geneva: World Health Organization, 2022.

13.Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance[J]. Clin Microbiol Infect, 2012, 18: 268-281. DOI: 10.1111/j.1469-0691.2011.03570.x.

14.Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis[J]. Lancet, 2022, 399: 629-655. DOI: 10.1016/ s0140-6736(21)02724-0.